SCHEMBL5322144

SCHEMBL5322144

CC(=O)CC(c1cccc(Cl)c1)N(C)Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TACR1 P25103 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 2/20 0.42
TMEM97 Q5BJF2 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
OPRM1 P35372 2/20 0.42
OPRL1 P41146 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
TP53 P04637 1/20 0.41
PTGES O14684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7368779 0.86 TDP1 (0.46) CYP3A4CYP2D6CYP2C19TACR1MEN1
SCHEMBL5321171 0.85 HTT (0.44) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5321030 0.85 LMNA (0.46) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL12861282 0.82 OPRM1 (0.49) MEN1KMT2AOPRM1OPRL1ALDH1A1
SCHEMBL5323549 0.81 GAA (0.43) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL15590888 0.71 L3MBTL1 (0.49) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL16788643 0.71 L3MBTL1 (0.49) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL5320282 0.71 MEN1 (0.48) CYP1A2CYP2C9NPSR1TACR1MEN1
SCHEMBL13452589 0.71 ADRA2B (0.50) NPSR1MEN1KMT2AGAAALDH1A1
SCHEMBL14017766 0.71 ADRA2B (0.50) NPSR1MEN1KMT2AGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007095756-A1 NOVEL CENTRAL-NERVOUS SYSTEM ACTING COMPOUNDS AND METHODS FOR THE TREATMENT OF CNS DISORDERS CLERA INC. (CA) 2007-08-30 WO disclosed